These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 15385046)

  • 21. Immunosuppressive treatment in haemophiliacs with inhibitors to factor VIII and factor IX.
    Nilsson IM; Hedner U
    Scand J Haematol; 1976 May; 16(5):369-82. PubMed ID: 951577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of NovoSeven during surgery on a haemophiliac with previous history of inhibitors.
    Saba HI; Morelli GA; Azam RR; Klein CJ; Letson GD
    Haemophilia; 2003 Jan; 9(1):131-6. PubMed ID: 12558792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.
    Négrier C; Menart C; Attali O; Petit PY; Lienhart A; Dechavanne M; Ingerslev J
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S135-41. PubMed ID: 9819045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents.
    Goldstein B; Geldziler B; Bjerre J; Seremetis S
    Transfus Apher Sci; 2008 Feb; 38(1):25-32. PubMed ID: 18267372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effective and safe use of recombinant factor VIIa (NovoSeven) in elderly mild haemophilia A patients with high-titre antibodies against factor VIII.
    Leebeek FW; Kappers-Klunne MC; Jie KS
    Haemophilia; 2004 May; 10(3):250-3. PubMed ID: 15086322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice.
    Franchini M; Mannucci PM
    Br J Clin Pharmacol; 2011 Oct; 72(4):553-62. PubMed ID: 21204915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.
    Mathias M; Khair K; Hann I; Liesner R
    Br J Haematol; 2004 May; 125(3):366-8. PubMed ID: 15086418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.
    Nilsson IM; Berntorp E
    Prog Clin Biol Res; 1990; 324():69-78. PubMed ID: 2106694
    [No Abstract]   [Full Text] [Related]  

  • 29. Consensus perspectives on surgery in haemophilia patients with inhibitors: summary statement.
    Rodriguez-Merchan EC; Rocino A; Ewenstein B; Bartha L; Batorova A; Goudemand J; Gringeri A; Joao-Diniz M; Lopaciuk S; Negrier C; Quintana M; Tagariello G; Tjonnfjord GE; Villar VA; Vorlova Z
    Haemophilia; 2004 Sep; 10 Suppl 2():50-2. PubMed ID: 15385047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab for adolescents with haemophilia and high titre inhibitors.
    Fox RA; Neufeld EJ; Bennett CM
    Haemophilia; 2006 May; 12(3):218-22. PubMed ID: 16643204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal.
    Sumner MJ; Geldziler BD; Pedersen M; Seremetis S
    Haemophilia; 2007 Sep; 13(5):451-61. PubMed ID: 17880429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prophylaxis in patients with haemophilia complicated by inhibitors].
    Paweł Ł
    Pol Merkur Lekarski; 2011 Mar; 30(177):211-4. PubMed ID: 21545000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elective orthopedic surgery for hemophilia patients with inhibitors: New opportunities.
    Rodriguez-Merchan EC; Wiedel Jd Jd; Wallny T; Caviglia H; Hvid I; Berntorp E; Rivard GE; Goddard Nj Nj; Querol F
    Semin Hematol; 2004 Jan; 41(1 Suppl 1):109-16. PubMed ID: 14872431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surgery in haemophilia and allied disorders.
    Anscombe AR
    Ann R Coll Surg Engl; 1970 Sep; 47(3):125-38. PubMed ID: 4922847
    [No Abstract]   [Full Text] [Related]  

  • 35. Experience of four UK comprehensive care centres using FEIBA® for surgeries in patients with inhibitors.
    Rangarajan S; Yee TT; Wilde J
    Haemophilia; 2011 Jan; 17(1):28-34. PubMed ID: 20642787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Minimizing factor requirements for surgery without increased risk.
    Schulman S; Loogna J; Wallensten R
    Haemophilia; 2004 Oct; 10 Suppl 4():35-40. PubMed ID: 15479370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of coagulation factor replacement with and without prednisolone in the treatment of haematuria in haemophilia and Christmas disease.
    Rizza CR; Kernoff PB; Matthews JM; McLennan CR; Rainsford SG
    Thromb Haemost; 1977 Feb; 37(1):86-90. PubMed ID: 320712
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Literature review of surgery management in inhibitor patients.
    Rodriguez-Merchan EC; Rocino A
    Haemophilia; 2004 Sep; 10 Suppl 2():22-9. PubMed ID: 15385043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive care for haemophilia.
    Kerr CB
    J R Coll Physicians Lond; 1971 Apr; 5(3):263-7. PubMed ID: 5163724
    [No Abstract]   [Full Text] [Related]  

  • 40. The current status of prophylactic replacement therapy in children and adults with haemophilia.
    Ljung R; Gretenkort Andersson N
    Br J Haematol; 2015 Jun; 169(6):777-86. PubMed ID: 25819695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.